Our studies with NHAs that were engineered to express TERT or to be ATRX-deficient in the absence of IDHmut suggest these 1H-MRS-detectable biomarkers are observed in the context of IDHmut-expressing low-grade gliomas. Here, ATRX is linked to central nervous system cancer.